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The phenomenon of T cell allorecognition is difficult to accommodate within the framework 
of a T cell repertoire positively selected in the thymus, unless allorecognition results from the 
cross-reactions of self-major histocompatibility complex restricted T cells. Herein, we demonstrate 
the dual specificity of cytotoxic T lymphocyte (CTL) clones for the immunodominant Epstein- 
Barr virus (EBV) epitope FLKGRAYGL, presented on HLA-B8, and the alloantigen HLA-B*4402. 
CTL which recognized peptide FLRGRAYGL in association with HLA-B8 could be reactivated 
in vitro from healthy individuals who had been exposed previously to EBV, using stimulator 
cells expressing the cross-reacting alloantigen  HLA-B*4402.  Limiting dilution analysis of the 
alloresponse to HLA-B*4402 in eight healthy individuals revealed that HLA-B8 +, EBV-sero + 
donors had higher CTL precursor  frequencies for alloantigen  HLA-B*4402  than EBV-sero- 
control donors. It is surprising that the majority (65-100%) of anti-FILA-B*4402 CTL, generated 
in limiting dilution mixed lymphocyte reactions between responder cells from HLA-B8 +, EBV- 
sero +  individuals  and  HLA-B*4402 +  stimulators,  also recognized the  EBV  CTL  epitope 
FLRGRAYGL/HLA-B8.  In contrast to previous studies showing extensive diversity in the T 
cell repertoire  against individual alloantigens,  these data demonstrate that the response to an 
alloantigen can be dominated by CTL cross-reactive with a single viral epitope, thus illustrating 
a possible mechanism for the frequent clinical association between herpesvirus exposure and graft- 
versus-host  disease after bone marrow transplants. 
T 
he response of T lymphocytes to intraspecies allelic vari- 
ants of MHC molecules, namely the alloresponse, is dis- 
played in vitro in the mixed lymphocyte reaction and in vivo 
during allograft rejection and GVHD. It is now dear that, 
in most cases, T cell recognition of alloantigens involves both 
the allo-MHC molecule and its associated peptide ligand (1). 
The vigor of the primary immune response to aUogeneic  MHC 
molecules is consistent with the high precursor frequency of 
T cells that respond to these molecules (2). Several models 
have been proposed to explain the high frequency of alloreac- 
rive T cells (1). The model first proposed by Matzinger and 
Bevan (3) is perhaps the easiest to incorporate within the frame- 
work of current knowledge of antigen presentation.  It pro- 
posed that a single MHC product can interact with many 
different cellular proteins  and that each individual "binary 
complex" can be recognized by a different T cell clone. Thus 
the variety  of antigenic peptides  processed from possibly 
hundreds of cellular and serum proteins  and presented  for 
allorecognition explains the magnitude of the response. This 
theory is supported by studies, mostly of murine alloresponses, 
showing extensive diversity in the TCR repertoire  against 
individual  alloantigens  (4-7). 
Responsiveness to foreign MHC molecules appears to violate 
the established dogma that only self-MHC-restricted T cells 
are positively selected in the thymus. It has therefore been 
suggested that the allospecific T cell repertoire overlaps with 
the repertoire which recognizes antigen in the context of self- 
MHC (1, 2). That is, allorecognition may result from mo- 
lecular mimicry, whereby the allogeneic MHC molecule can 
resemble the self-MHC complexed with a nominal antigen. 
Several examples of CTL clones with dual specificity of this 
kind support this contention (8). Analyses of multiple cloned 
T cell populations  have demonstrated that between 20 and 
60% of antigen-specific, MHC-restricted T cell clones cross- 
react with alloantigens (9, 10). It has also been shown that 
approximately half of a "primary" alloresponse is contributed 
by previously primed T cells, which by definition, must be 
self-MHC restricted  (11, 12). 
Two previous studies have demonstrated CTL with dual 
specificity  for autologous EBV-transformed cell lines and HLA 
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fects more than 90% of all humans. In developed countries, 
primary infection with EBV is often ddayed until adoles- 
cence, when it is usually dinically evident as in~tious mono- 
nucleosis (15). The virus persists systemically as a latent in- 
fection in B cells and is apparently under the immune control 
of EBV-specific CTL that recognize epitopes derived from 
an array of latent viral proteins  (15). Studies of in vitro- 
reactivated CTL have demonstrated very high frequencies of 
EBV-specific memory T calls in PBMC from normal asymp- 
tomatic  EBV-sero +  individuals  of between  1/3,000  and 
1/400 (16), precursor frequencies  that are not dissimilar to 
those estimated for allospecific CTL in humans (17). This 
report describes the antigen mimicry between HLA-B*4402 
as an alloantigen, and an immunodominant EBV-encoded 
CTL epitope that binds to HLA-B8 and that has been mapped 
to a nine-amino acid peptide from the EBV nuclear antigen 
EBNA 3 (18). We demonstrate that the response  to an al- 
loantigen can be dominated by CTL cross-reactive  with a 
single EBV epitope which contrasts with previous studies 
which concluded that alloresponses  are heterogenous. This 
illustration that memory T cells to a herpesvirus can signi- 
ficantly influence an alloresponse  is discussed with reference 
to previous studies establishing herpesvirus exposure as an 
important risk factor for GVHD after bone marrow transplant. 
Materials and Methods 
Establishment and Maintenance of Cell Lines.  CTL clones LC13 
and SC17 were isolated from EBV-sero  § donors LC (HLA-A1, -, 
B8,B18,DR3,DRll)  and SC  (HLA-A1,A31,BS,B51,DR3,DR4) 
after in vitro  stimulation of fresh PBMC with the autologous 
lymphoblastoid cell lines (EBV-LCL)  1 transformed with EBV de- 
rived from the IARC-BL74 cell line (18). Both CD8 + clones are 
HLA-B8 restricted and recognize the EBV CTL epitope FLR- 
GgAYGL (19). 
PHA blasts were generated by stimulating PBMC with PHA 
(Commonwealth  Serum  Laboratory,  Melbourne,  Australia) and after 
3 d, growth medium (10% FCS/R.PMI 1640) containing MLA- 
144 supematant and riD2 (20, 21) was added. PHA blasts were 
propagated with biweekly replacement of rlL-2 and MLA-144 su- 
pernatant (PHA free) for up to 8 wk. 
EBV-LCL  were established by exogenous A-type EBV transfor- 
mation of peripheral B cells and maintained in growth medium 
(22). All cell lines were regularly screened for mycoplasma  con- 
tamination. Blood donors used in this study were healthy labora- 
tory staff and were tested for previous EBV exposure using stan- 
dard methods to detect IgG antibody to the EBV capsid antigen 
(viral capsid antigen) (23). 
Cytotoxicity Assay.  CTL clones were screened in the standard 
5-h chromium release assay  (E/T ratio 1:1 unless otherwise stated) 
(18). In some experiments, nCr-labded  PHA blast targets were 
incubated for 45 min with or without peptide epitope FLRGRA- 
YGL (50/zg/ml) before effectors  were added. The peptide was syn- 
thesized using the simultaneous multiple peptide synthesis tech- 
nique originally described  by Houghten (24). In some experiments, 
target ceils were incubated with mAb to HLA class I and II before 
CTL addition (W6/32, American  Type  Culture Collection  (ATCC) 
Abbreviations used in this paper: CTLp, CTL precursor; LCL, lympho- 
blastoid cell line; LDA, limiting dilution analysis. 
HB-95 and antibody 2.06, ATCC HB-104; final  dilution of 1/20 
of ascites fluid). For cold target inhibition assays,  varying numbers 
of unlabeled targets were added to labeled targets before the addi- 
tion of effector cells. 
Polyclonal CTL populations were also used as effectors. These 
were generated by culturing PBMC with 3,-irradiated (2,000 Lad) 
PBMC from an HLA-mismatched  donor (responder/stimulator  ratio 
2:1) for 7 d. At this time, the stimulated T cells were harvested 
by E-rosetting and used in the standard 5-h chromium release assay 
(E/T ratio 20:1). In these experiments, peptide FLRGRAYGL  was 
washed off  target cells before plating out so that the large number 
of effector cells would not bind peptide and compete with lysis 
of slCr-labeled targets. 
Limiting Dilution Analysis.  PBMC were distributed in graded 
numbers from 5  x  103 to 5  x  104 cells per well (EBV-sero- 
responders) or from 2.5  x  103 to 2  x  104 cells per well (EBV- 
sero § responders) in round-bottomed microtiter plates. Approxi- 
mately 5  x  104 7-irradiated (2,000 Lad) PBMC from a HLA- 
B'4402 + donor (SJ: HLA-A2, A3, B7, B'4402,  DK1, -) were 
added to give a total volume of 100 #1. 24 or 36 replicates were 
used at each  concentration  in each  experiment, and an equal number 
of  control wells  were set up in which no stimulator cells  were added. 
Cultures were fed on days 4 and 7 with 50 #1 of medium sup- 
plemented with 20 U of  rlL-2 and 30% (vol/vol) supernatant from 
MLA-144 cultures. On day 10, each CTL microculture was split 
into three replicates and used as effectors in a standard 5-h SlCr- 
release assay against HLA-B8  + PHA  blasts (SC  PHA blasts: 
HLA-A1,A31,BS,B51,DR3,DR4), precoated with peptide FLR- 
GRAYGL or left uncoated, and HLA-B*4402  + PHA blasts (PW 
PHA blasts: HLA-A1,  A28, B8, B'4402, DR3, DIL6). Wells  were 
scored as positive when the percent specific  chromium release ex- 
ceeded the mean release from control wells by 3 SD. Limiting dilu- 
tion analysis (LDA) was performed by the method of maximum 
likelihood estimation (25). Data from all experiments were com- 
patible with the hypothesis of single-hit kinetics (p ;>0.4) and 
precursor estimates are given with 95% confidence limits. 
Results 
CTL Clones Show Dual Specificity  for an EBV Epitope Presented 
on HLA-B8 and the Alloantigen  HLA-B*4402.  12  CD8 + 
CTL dones were isolated from four HLA-B8 +, EBV-sero + 
unrelated individuals after in vitro stimulation of PBMC with 
their autologous EBV-LCL. All clones that recognized the 
EBV epitope FLRGRAYGL, presented on HLA-B8, also  lysed 
uninfected target cells (PHA blasts)  expressing  the alloan- 
tigen HLA-B*4402. Fig. 1 illustrates the spedficity of one 
such clone from donor LC (CTL LC13).  HLA-B8 + cells 
were recognized by the CTL if infected with EBV (Fig.  1 
A, TARGET EBV-LCL) or if peptide FLRGRAYGL was 
added exogenously to PHA blast targets (Fig. 1 B), whereas 
HLA-B*4402 + cells were lysed with or without EBV in- 
fection. Cells expressing other HLA antigens, induding the 
other major subtype of HLA-B44, B'4403, were not recog- 
nized.  The  addition of peptide  FLRGRAYGL to  HLA- 
B'4402 + targets did not significantly increase levels of CTL 
lysis unless the targets were also  HLA-B8 + . 
Fig. 2 shows the cross-reactivity of a CTL done (SC17), 
raised against the autologous EBV-LCL and sdected for rec- 
ognition ofpeptide FLRGRAYGL, isolated from another un- 
related HLA-B8 + donor. The target cells were again EBV- 
1156  T Cells Cross-reactive with a Viral Epitope Dominate an AUoresponse TARGET 
HLA TYPE:  EBV-LCL: 
A1,-,B~IS, DR3,11  LC 
AI,31,B~51,DR.3.4  SC 
AI,2.~51,DR?  JS 
A2,24,BZ35,DR2,11  NB l 
A3,11,B35,51,DR4,53  RP 
A3,11,BZ52,DR2,-  GH 
A2,24,B51,62,DR2,7  ASs 
A1,24,BT,1ZDRS,7  TS 
A2,11,B7,15,DPJ,4  JA 
A29,32,B35,45,DR4,5  CMI 
A2,-,BZ *4402.DP,  J,3  LL 
A1],24,BZ *4402.DR1,2  CMo 
A2,3,BZ "4402.DR1,-  SJ 
A2,23,B35,*4403,DRI.11  CS - 
A31.33.B14. "4403.DR1.6  LO 
TARGET 
PHA 
HLA TYPE:  B~S: 
AI,-,J~IS, DR.3,11  LC 
AI,31,J~51,DR3,4  SC 
A2,26,J~38,DR2,3  WY 
A3,30,Bg14,DR3,5  BH 
Al,lI,BS.51,DR3,7  IM 
A2,24,BZ35,DR2,11  NB 
A2,24,B51,62,DR2,7  ASa 
A2,30,B35,57,DR4,7  SB 
A2,3,BZ "4402.DR1,-  SJ 
A2,-,BT, "4402.DRI,3  LL 
A1,2.B~ *4402.DP-,3.4  CF 
AI,28,J~ *4402.DR3,6  PW 
A2,23.B35.*4403,DRI.]I  CS 
AI I,29,BZ "4403,DR?  PM 
I 
A 
1'0  20  30  40 
%Lysls 
B 
10  20  30  40 
% Lysls 
1 
Figure  1.  Lysis by CTL clone LC13 of EBV-LCL (A) and PHA blast 
targets (B) in the absence (I)  or presence (F]) of peptide FLRGRAYGL 
(E/T ratio  =  1:1). 
LCL (Fig.  2 A) and PHA blasts in the presence or absence 
of peptide  FLRGRAYGL  (Fig.  2  B),  tested  at  a range  of 
effector/target ratios. A similar pattern oflysis to that shown 
in  Fig.  1  for  clone  LC13  was  observed.  The  addition  of 
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Figure  2.  Lysis by CTL  clone SC17 of EBV-LCL  (A)  and PHA  blast 
targets (B) in the absence or presence of peptide  FLRGRAYGL  over a 
range of E/T ratios. 
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Figure  3.  Cold target competition of CTL lysis by clone LC13 of a 
HLA-B*4402 + EBV-LCL (LL LCL - A) and a HLA-B8 + EBV-LCL (LC 
LCL - B)  (effector/hot  target  ratio  =  1:1).  Specific cytotoxicity of the 
target cells in the absence of competing cells was 19.0%  for LL LCL and 
42.4%  for LC LCL. 
in  Fig.  1  for  clone  LC13  was  observed.  The  addition  of 
anti-class  I  antibody  to  HLA-B*4402 +  and  -B8 +  targets 
significantly  reduced  lysis  by  these  CTL  clones,  whereas 
anti-class  II  antibody had little effect  (data  not  shown). 
Cold target competition experiments were carried out on 
CTL LC13 to demonstrate that the dual reactivity pattern 
was not caused by a contaminating  CTL population. Lysis 
by CTL LC13 of a HLA-B*4402 + cell line (Fig.  3 A) and 
the autologous EBV-LCL (Fig. 3 B) was more significantly 
inhibited by unlabeled HLA-B8 + and -B'4402 + EBV-LCL 
than by cell lines not expressing these antigens.  The cross- 
reactivity is,  therefore,  clearly  mediated by the same TCR 
on a single population of CTL. Higher cold/hot target ratios 
were necessary to compete with lysis of the autologous EBV- 
LCL than the HLA-B*4402 + cell line,  suggesting that the 
self-HLA-restricted  recognition by CTL LC13 is more e~cient 
than  the allorecognition. 
EBV Memory  T  Cells Can Be Reactivated In  Vitro Using 
Allostimulation.  Studies in this laboratory have shown that, 
of  those  tested,  the  majority  of  HLA-B8 +,  EBV-sero + 
individuals  (but  not  EBV-sero-  individuals)  carry  EBV 
memory CTL that recognize the epitope FLRGRAYGL (our 
unpublished observations). To determine if these memory cells 
could be reactivated using allostimulation, PBMC from two 
HLA-B8 +, EBV-sero + (ASu and LC) and two EBV-sero- 
(BHo and MW)  individuals were stimulated in vitro with 
y-irradiated PBMC from HLA-mismatched donor DM (HLA- 
A24, A29, B'4402,  B47, DR1, DR7).  The resulting poly- 
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Figure 4.  Lysis  of PHA blast targets, with (U]) or without (11) pep- 
tide FLRGRAYGL presensitization, by polyclonal CTL raised from two 
EBV-sero  +, HLA-B8 + and two EBV-sero- individuals after stimulation 
with PBMC from HLA mismatched,  HLA-B*4402 + donor DM (E/T 
ratio  =  20:1). 
clonal CTL populations were tested for lysis of PHA blast 
targets  in  the presence or  absence of EBV peptide  FLR- 
GRAYGL. Effectors generated from EBV-sero + responders 
not only gave significant lysis of targets sharing HLA-B*4402 
with the stimulator PBMC (with or without exogenous pep- 
tide) but also lysed HLA-B8 + PHA blasts  in the presence 
of the EBV peptide (Fig.  4).  In contrast, CTL from EBV- 
sero-  donors lysed HLA-B*4402 +  targets less  efficiently, 
and showed negligible recognition of FLRGRAYGL/HLA- 
B8 (Fig. 4). CTL clones that recognize EBV epitope FLR- 
GRAYGL have also been raised from HLA-B8 +, EBV-sero + 
donor LC after in vitro stimulation with allogeneic PBMC 
expressing HLA-B*4402. The pattern of lysis for these clones 
parallels that of CTL clones LC13 and SC17 (Figs.  1 and 2) 
which were established after stimulation with the autologous 
EBV-LCL (data not shown). These data demonstrate that 
the alloantigen HLA-B*4402 can restimulate EBV memory 
CTL  (which recognize peptide  FLRGRAYGL)  in  HLA- 
B8 +, EBV-sero + individuals. 
CTL Precursor  Frequencies  for the A lloantigen HLA-B*4402 
in EBV-sero + HLA-B8 +,  and EBV-sero-  Individuals.  Pre- 
cursor  frequency estimates  of CTL  against  EBV  epitope 
FLRGRAYGL/HLA-B8 previously have been shown to be 
high  (1  in  7,530  to  2,200  PBMC)  in  most  EBV-sero +, 
HLA-B8 +  individuals  (26,  and  our unpublished  observa- 
tions).  To determine if these individuals also have elevated 
CTL precursor (CTLp) frequencies against alloantigen HLA- 
B'4402,  PBMC  from four EBV-sero +,  HLA-B8 + donors 
were  stimulated with  y-irradiated  PBMC  from  a  HLA- 
B'4402 + donor in LDA. PBMC from four EBV-sero- in- 
dividuals, which should not include memory CTLp for EBV 
epitope FLRGRAYGL/HLA-B8, were also analyzed for com- 
parison. Effector wells were tested against target PHA blasts 
sharing only HLA-B*4402 with the stimulator cells. As shown 
in Fig. 5, the frequencies of CTLp which responded to HLA- 
B'4402  in four EBV-sero +, HLA-B8 + individuals were 1 
per 10,100, 14,900,  17,600,  and 13,800.  These frequencies 
were significantly higher  than  those  estimated for  EBV- 
sero- donors (1 per 32,700,  196,000, 328,000,  and 334,000). 
These data suggest that prior exposure to EBV might influence 
CTLp frequencies to an alloantigen. 
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Figure 5.  Comparative CTLp frequencies in four 
EBV-sero-  and  four  EBV-sero  +,  HLA-B8 +  in- 
dividuals for aUoantigen HLA-B*4402, using LDA. 
Reciprocal values of responder frequencies (pf-a) are 
indicated. The 95% confidence limits for each pf-1 
are as follows: (ASu) 7,500-13,500;  (MW) 23,600- 
45,200; (LC) 10,600-20,900; (B/-/) 144,000-295,000; 
(IM)  12,600-24,700;  (IC)  142,000-755,000;  (/IF) 
9,900-19,200;  and (IS) 173,000-656,000. 
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Figure  6.  Split-well analysis of CTL micro- 
cultures generated in LDA from responder cell 
concentrations below the estimated CTLp fre- 
quencies  for  alloantigen  HLA-B*4402  and 
which were positive for HLA-B*4402 recog- 
nition. Each point on the graph indicates the 
levels of lysis for each CTL microcuhure of two 
target  populations:  PW  PHA blasts,  which 
share only HLA-B*4402 with the stimulator 
cells (y-axis); and SC PHA blasts preincubated 
with peptide FLRGRAYGL, which are HLA- 
B8 + but which share no HLA antigens with 
the stimulators (x-axis).  SC PHA blasts were 
also used as targets without peptide presensiti- 
zation (data not shown);  these were lysed by 
<5%  of CTL  microcultures,  and data  from 
these CTL  were  omitted  from  the analysis. 
(Dashed venkal lines) Values calculated from con- 
trol wells to define positive cytotoxic activity 
against  SC  PHA  blasts  plus  peptide  FLR- 
GRAYGL. 
The Majority of CTLp for Alloantigen HLA-B*4402 in HLA- 
B8 §  EBV-sero § Individuals Are EBV Memory  T  Cells that 
Cross-react with the Alloantigen.  To determine if the higher 
frequencies of CTLp for alloantigen HLA-B*4402 in the EBV- 
sero +, HLA-B8 § individuals were a result of cross-reacting 
EBV memory T cells, "split-well" LDA assays were conducted. 
Each microculture in the above LDA was divided and assayed 
separately for CTL activity against HLA-B8 §  PHA blasts 
(SC PHA blasts),  with and without peptide FLRGKAYGL, 
and HLA-B*4402 §  PHA blasts  (PW PHA blasts).  These 
target cells shared no HLA antigens, other than HLA-B*4402 
in the case of the latter target, with the stimulator cells. Fig. 
6 shows the reactivity pattern of CTL microcultures derived 
from responder cell concentrations below the estimated CTLp 
frequencies for alloantigen HLA-B*4402  (thus, most were 
likely to be derived from one anti-HLA-B*4402 precursor) 
and which were positive for HLA-B*4402 recognition. The 
majority of CTL from EBV-sero §  HLA-B8 §  individuals 
which recognized HLA-B*4402 also lysed HLA-B8 § targets 
presensitized with peptide FLRGR_AYGL (97,  100, 92, and 
65%  of CTL microcultures for donors ASu, LC,  IM, and 
AF, respectively). In contrast, only 1/55 CTL microcultures 
with  anti-HLA-B*4402  activity,  raised  from  EBV-sero- 
donors, cross-reacted with the HLA-B8-restricted EBV CTL 
epitope (data not shown). These data demonstrate that a re- 
sponse to an alloantigen can be dominated by CTL cross- 
reactive with a single viral epitope. 
Discussion 
The recognition of specific allo-MHC molecules by CTL 
clones generated in response to antigen presented by autolo- 
gous cells, as described for CTL LC13 and SC17 (Figs. I and 
2) and in several previous reports (8), suggests that allorecog- 
nition represents the cross-reactions of self-MHC-restricted 
T cells. This report extends evidence in support of this view 
with the demonstration that T cells which recognize an EBV 
epitope could be restimulated in vitro from EBV-exposed in- 
dividuals using allostimulation  (Fig. 4). This observation raised 
the possibility that the high frequency of memory T  cells 
for the EBV epitope FLRGRAYGL,  which appear to  be 
present in most EBV-sero +, HLA-B8 + individuals (26,  and 
our unpublished observations), could significantly influence 
the response to HLA-B*4402 as an alloanfigen. Indeed, con- 
siderably more anti-HLA-B*4402 CTLp were detected in four 
EBV-sero +, HLA-B8 + donors used in this study compared 
with four EBV-sero-  donors (Fig.  5). Although precursor 
frequencies ofT cells reactive to particular MHC alloantigens 
in humans vary considerably between unrelated individuals 
(27),  "split-well" analysis  of CTL lines raised from single 
anti-HLA-B*4402  CTLp confirmed an important role for 
EBV memory T cells in the response to that alloantigen in 
EBV-sero § , HLA-B8 + donors. The majority of anti-HLA- 
B'4402 CTL from these individuals also recognized the EBV 
epitope presented by HLA-B8 (Fig. 6). These results suggest 
that FLRGRAYGL-specific memory T  cells from different 
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of cross-reacting with HLA-B*4402. This is consistent with 
the results of a parallel study in this laboratory which has 
demonstrated TCR sequence identity between FLtLGRAYGL- 
specific CTL clones raised from four unrelated individuals 
after in vitro stimulation with their autologous EBV-LCL 
(Argaet, V., C. Schmidt, S. Burrows, A. Suhrbier, D. Moss, 
and I.  Misko, manuscript in preparation). 
The potency of the alloresponse is thought to reflect the 
profusion and diversity of potentially antigenic peptides nat- 
urally presented on MHC molecules, which stimulate a large 
variety of T cell donotypes (1, 2). An early study supporting 
this model showed that a murine aUoresponse to a single MHC 
antigen contained a minimum of 50 different T cell specifidties 
(4).  Repertoire diversity has also been demonstrated at the 
level of expression of different TCR genes (5-7).  We have 
shown that, in some individuals, a highly restricted T  cell 
repertoire is activated for a human alloantigen. The strength 
of the anti-HLA-B*4402 alloresponse in these individuals is 
therefore not induced by multiple alloantigenic determinants 
but by the high frequency of memory CTL to a single EBV 
epitope which fortuitously cross-reacts with the alloantigen. 
Of the two major subtypes of HLA-B44,  B'4402  and 
B'4403, only the former was recognized by the cross-reactive 
CTL. These two subtypes differ by a single amino acid at 
position 156, the most variable residue of the MHC oe2 do- 
main helix (28).  It is interesting to note that HLA-B*4402 
shares aspartic acid with HLA-B8 at this position whereas 
HLA-B*4403  has the consensus residue leucine (28),  sug- 
gesting that the aspartic acid may be critical for recognition 
by these clones. Although the side chains of amino acids at 
position 156 point into the peptide-binding groove, they may 
remain partially accessible to direct contact with the TCR 
(29).  Indeed, TCK contact with the MHC at position 156 
appears to occur for several EBV-specific CTL clones recently 
isolated in our laboratory, which recognize an EBV epitope 
known to bind to both major subtypes of HLA-B44, but 
which lyse only target cells presenting the EBV epitope in 
association  with  HLA-B*4402  and  not  HLA-B*4403 
(Burrows, S., K. Khanna, and D. Moss, manuscript in prep- 
aration). 
The results presented herein support other evidence (11, 
12) that memory T  cells may play a major role in human 
aUoresponses. The frequency of memory CTL to the common 
herpesvirus, EBV and human cytomegalovirus (HCMV), in 
healthy immune people are higher than those reported for 
any other virus (16, 30), with the possible exception of HIV 
(31).  Virtually 100%  of healthy EBV-sero + and HCMV- 
sero + individuals show a clear virus-specific CTL response 
in vitro (32, 33). The potency of the response to these viruses 
probably relates to their lifetime persistence and the repeated 
antigenic challenge with multiple viral epitopes. When this 
is considered in the context of reports that at least 60% of 
HLA-restricted CTL clones cross-react with aUoantigens (10), 
it is not unlikely that memory T cells to these viruses signi- 
ficantly influence human aUoresponses. It is interesting to note 
that pretransplant serological studies have established herpes- 
virus exposure as an important risk factor for GVHD after 
bone marrow transplant (34). Expanding on the present study, 
it will be important to establish  what proportion of CTL 
clones reactive to other allo-HLA antigens cross-react with 
autologous cells infected with herpesviruses such as EBV and 
HCMV.  In addition,  a more extensive analysis comparing 
alloreactive CTLp frequencies between individuals sero- or 
sero + for the common herpesviruses, may confirm an im- 
portant correlation between virus exposure and alloreactivity. 
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